Sign in Subscribe
Pharmaceutical industry

Nine Top Biopharmaceutical Companies Pledge Commitment to Safety and Efficacy of COVID-19 Vaccines

Strategic Insights

— 1 min read

Nine of the world's top biopharmaceutical companies have come together to assure the public that the COVID-19 vaccines they are developing have undergone rigorous testing and meet safety and efficacy standards set by regulatory bodies. The CEOs of AstraZeneca, BioNTech, GlaxoSmithKline plc, Johnson & Johnson, Merck (MSD), Moderna Inc, Novavax Inc, Pfizer Inc, and Sanofi have signed a pledge reaffirming their commitment to upholding the scientific process in the development and testing of COVID-19 vaccines.

Key Takeaways:

  • The nine top biopharmaceutical companies have pledged to prioritize the safety and well-being of vaccinated individuals, adhering to high scientific and ethical standards in clinical trials and manufacturing processes.
  • The companies have committed to submitting vaccines for approval or emergency use authorisation only after demonstrating safety and efficacy through Phase 3 clinical trials that meet regulatory requirements, such as those set by the US FDA.
  • The pledge highlights the companies' experience in clinical development and regulatory rigor, with more than 70 novel vaccines developed, which have helped to eradicate complex and deadly public health threats.
  • Work towards ensuring a sufficient supply and range of vaccine options, including those suitable for global access, to gain public confidence in the rigorous scientific and regulatory process.
  • Regulatory agencies, such as the US FDA, will ultimately review and determine the safety and efficacy of COVID-19 vaccines, adhering to established guidance and criteria.
  • The pledge comes at a crucial time, with the world relying on the swift development and distribution of vaccines to combat the COVID-19 pandemic.

Statistics:

  • More than 70 novel vaccines have been developed by the nine participating companies, which have helped to eradicate complex and deadly public health threats.
  • Nine biopharmaceutical companies CEOs have signed the pledge to uphold the integrity of the scientific process in vaccine development.
  • The companies have committed to submitting vaccines for approval or emergency use authorisation only after demonstrating safety and efficacy through Phase 3 clinical trials.
  • Regulatory agencies, such as the US FDA, require vaccines to undergo rigorous testing, including large-scale, high-quality clinical trials with diverse participant populations.

Sources:

  • AstraZeneca
  • BioNTech
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck (MSD)
  • Moderna Inc
  • Novavax Inc
  • Pfizer Inc
  • Sanofi
  • Contify.com
  • Domain-b.com

Read more